DOCSLIB.ORG

What Side Effects Can Be Seen with Its Use?

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
What Side Effects Can Be Seen with Its Use? Opiate Antidiarrheals – Paregoric, Diphenoxylate HCl/Atropine Sulfate, Loperamide HCl Other names for these drugs include Paregoric (camphorated tincture of opium), Opium Tincture, Logen®, Lomotil®, Lonox®, Lomanate®, Pepto Diarrhea Control®, Kaopectate II Caplets®, Imodium A-D caplets®, Neo-Diaral®, Diar-aid Caplets®, K-Pek II. How Is This Medication Useful? Among their other actions, opiates inhibit movement of the gastrointestinal tract, calm excessive GI propulsion associated with diarrhea. They also decrease secretion of fluids by the intestine, and may also enhance absorption of fluid by the intestines. These drugs are used mostly in dogs, and their use in cats is controversial. Many veterinarians do not recommend their use in cats. Generally, onset of action occurs within 45 minutes to one hour after dosing and is sustained for 3-4 hours. In dogs, loperamide (Imodium) reportedly has a faster onset of action and longer duration of action than diphenoxylate (Lomotil). Are There Conditions or Times When Its Use Might Cause More Harm Than Good? • All opiates should be used with caution in patients with low thyroid function (hypothyroidism), severe kidney disease, Addison's disease, and in geriatric or severely debilitated patients. • Opiate antidiarrheals should not be used in cases where the patient is allergic to narcotic pain killers analgesics, nor in patients taking monoamine oxidase inhibitors (selegiline, Anipryl, L- deprenyl, etc). • They should not be used in patients with diarrhea caused by a toxic ingestion or infection, until the toxin is eliminated from the GI tract (these drugs may cause toxins to be retained in the body longer). • Opiate antidiarrheals should be used with caution in patients with head injuries or other brain disorders associated with increased pressure in the brain or spinal fluid, and acute abdominal conditions (e.g., colic) as it may obscure the diagnosis or clinical course of these conditions. • It should be used with extreme caution in patients suffering from respiratory disease or from acute respiratory dysfunction (e.g., pulmonary edema secondary to smoke inhalation). • Opiate antidiarrheals should be used with extreme caution in patients with liver disease with symptoms of hepatic encephalopathy. Hepatic coma may result. • Many veterinarians recommend not using diphenoxylate or loperamide in dogs weighing less than 5 pounds, but this is probably a result of difficulty in dosing this small. Liquid forms may be used for small dogs safely. • Loperamide should be used with caution in herding breeds (e.g., Collies) who may be overly sensitive to it. • If your animal has any of the above conditions, talk to your veterinarian about the potential risks of using the medication versus the benefits that it might have. What Side Effects Can Be Seen With Its Use? • Animal studies have not yet demonstrated risk to the fetus during pregnancy by taking loperamide. • Animal studies have shown an adverse effect on the fetus by diphenoxylate/atropine, and its use is not recommended in pregnant dogs and cats. • It is not known whether loperamide is excreted in maternal milk. Safety during nursing has not been established. Exercise caution when administering diphenoxylate HCl with atropine to nursing patients. Diphenoxylic acid may be excreted in maternal milk and atropine is excreted in maternal milk, but effects on the infant may not be significant. • In dogs, constipation, bloat and sedation are the most likely adverse reactions encountered when usual doses are used. • Potentially, paralysis of the intestines, toxicity caused by paralysis of the colon, pancreatitis or neurologic problems could be seen. • Use of antidiarrheal opiates in cats is controversial; this species may react with excitatory behavior. • Overdosage of the opiate antidiarrheals could result in neurologic problems, cardiovascular, GI or respiratory problems. Because the opiates may significantly reduce GI movement, absorption from the GI may be delayed and prolonged. Naloxone may be necessary to reverse the opiate effects. Massive overdoses of diphenoxylate/atropine sulfate may also induce atropine toxicity (increased heart rate, dried secretions, red skin, etc) How Should It Be Given? • Other brain depressants (e.g., anesthetic agents, antihistamines, phenothiazines, barbiturates, tranquilizers, alcohol, etc.) may cause increased nervous system or respiratory depression when used with opiate antidiarrheal agents. • Opiate antidiarrheal agents should not be used in patients receiving monoamine oxidase (MAO) inhibitors (rarely used in veterinary medicine) for at least 14 days after receiving MAO inhibitors. These drugs include selegiline, Anipryl, and L-deprenyl. • The successful outcome of your animal’s treatment with this medication depends upon your commitment and ability to administer it exactly as the veterinarian has prescribed. Please do not skip doses or stop giving the medication. If you have difficulty giving doses consult your veterinarian or pharmacist who can offer administration techniques or change the dosage form to a type of medication that may be more acceptable to you and your animal. • If you miss a dose of this medication you should give it as soon as you remember it, but if it is within a few hours of the regularly scheduled dose, wait and give it at the regular time. Do not double a dose as this can be toxic to your pet. • Some other drugs can interact with this medication so tell your veterinarian about any drugs or foods that you currently give your animal. Do not give new foods or medications without first asking your veterinarian. • Dogs and cats take Paregoric two to three times daily, and should probably take it for no longer than 5 days at a time. • Dogs take Diphenoxylate/Atropine two to three times daily, and should probably take it for no longer than 5 days at a time. • Cats take loperamide two times daily. What Other Information Is Important About This Medication? • Paregorics should be stored in tight, light-resistant containers. Avoid exposure to excessive heat or direct exposure to sunlight. • Diphenoxylate/atropine tablets and oral solution should be stored at room temperature in well- closed, light-resistant containers. Liquids should not be frozen. • Loperamide capsules or oral solution should be stored at room temperature in well-closed containers. It is recommended that the oral solution not be diluted with other solvents. References: Plumb's Veterinary Drug Handbook .
Load more

Recommended publications
  • Palliative Care Case of the Month
    PALLIATIVE CARE CASE OF THE MONTH “Treating Non-Infectious Diarrhea” by Robert Arnold, MD Volume 19, No. 98 August, 2019 Case 1: Mr. Jones is a 58-year-old man with short gut Three drugs are used because of their ability to slow down the syndrome. Palliative Care was consulted for goals of care, gut, allowing for more time for absorption of intestinal fluids a however quickly it became clear uncontrolled diarrhea was a decrease of diarrhea. The most well-know is loperamide, a larger priority. He said having to change the bag every few hours synthetic opiate which has minimal absorption. The dosing is 4 completely interfered with his living a normal life. He said, “I’d mg after one’s first bowel movement and then 2 mg after every rather die than have all of this diarrhea.” unformed stool, up to 16 mg (in palliative care patients there is some data for use up to 54 mg).9, 10 Loperamide should be Case 2: A 62-year-old woman with non-small cell lung cancer continued for 12 hours after diarrhea is stopped. Adverse effects is receiving immunotherapy. She has done quite well but is include mostly constipation, abdominal cramps, nausea and distressed by her diarrhea. She tried Lomotil and Imodium but rarely CNS effects like fatigue or dizziness. Cases of torsades de neither worked. When seeing her palliative care doctor, she said, pointes and death have been reported with higher than “It isn’t worth treating my cancer if I can’t live a normal life.” 9 recommended doses.
    [Show full text]
  • Anti-Diarrheal Activity and Brine Shrimp Lethality Bioassay of Methanolic Extract of Cordyline Fruticosa (L.) A
    Naher et al. Clinical Phytoscience (2019) 5:15 https://doi.org/10.1186/s40816-019-0109-z ORIGINAL CONTRIBUTION Open Access Anti-diarrheal activity and brine shrimp lethality bioassay of methanolic extract of Cordyline fruticosa (L.) A. Chev. leaves Sharmin Naher1*, Md. Abdullah Aziz1, Mst. Irin Akter2, S. M. Mushiur Rahman1, Sadiur Rahman Sajon1 and Kishor Mazumder1,3 Abstract Background: Cordyline fruticosa (L.) A. Chev. (Asparagaceae) is a plant which is traditionally used for the treatment of cough, bloody cough, diarrhea, dysentery, high fever, difficulties in urine, bloody urine, small pox, madness, skin eruptions, joint pains, rheumatic bone pains, sore throat, neck pain, bleeding hemorrhoids and inflammation in the digestive tract. Therefore, the present work aims to investigate the antidiarrheal and cytotoxic activities of methanolic extract of Cordyline fruticosa leaves in mice and brine shrimp, respectively. Methods: The effects of the methanol extract of Cordyline fruticosa leaves (MCFL) on castor oil-induced diarrhea, magnesium sulphate induced diarrhea and charcoal meal test in mice were investigated. In addition, brine shrimp lethality bioassay method was used to evaluate cytotoxic activity of MCFL. Results: In castor oil induced diarrheal test, MCFL at the dose of 200, 400 and 800 mg/kg body weight significantly (∗P< 0.05, versus control) and dose-dependently reduced the frequency of diarrhea. The frequency of magnesium sulphate-induced diarrhea was significantly reduced by MCFL at the dose of with 800 mg/kg. In the charcoal meal test, the extract at the dose of 400 and 800 mg/kg body weight significantly (∗P< 0.05) reduced the distance travelled by charcoal along the intestinal tract when compare with control.
    [Show full text]
  • FDA Warns About an Increased Risk of Serious Pancreatitis with Irritable Bowel Drug Viberzi (Eluxadoline) in Patients Without a Gallbladder
    FDA warns about an increased risk of serious pancreatitis with irritable bowel drug Viberzi (eluxadoline) in patients without a gallbladder Safety Announcement [03-15-2017] The U.S. Food and Drug Administration (FDA) is warning that Viberzi (eluxadoline), a medicine used to treat irritable bowel syndrome with diarrhea (IBS-D), should not be used in patients who do not have a gallbladder. An FDA review found these patients have an increased risk of developing serious pancreatitis that could result in hospitalization or death. Pancreatitis may be caused by spasm of a certain digestive system muscle in the small intestine. As a result, we are working with the Viberzi manufacturer, Allergan, to address these safety concerns. Patients should talk to your health care professional about how to control your symptoms of irritable bowel syndrome with diarrhea (IBS-D), particularly if you do not have a gallbladder. The gallbladder is an organ that stores bile, one of the body’s digestive juices that helps in the digestion of fat. Stop taking Viberzi right away and get emergency medical care if you develop new or worsening stomach-area or abdomen pain, or pain in the upper right side of your stomach-area or abdomen that may move to your back or shoulder. This pain may occur with nausea and vomiting. These may be symptoms of pancreatitis, an inflammation of the pancreas, an organ important in digestion; or spasm of the sphincter of Oddi, a muscular valve in the small intestine that controls the flow of digestive juices to the gut. Health care professionals should not prescribe Viberzi in patients who do not have a gallbladder and should consider alternative treatment options in these patients.
    [Show full text]
  • Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017
    Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 BR 111 / 2017 The Minister responsible for health, in exercise of the power conferred by section 48A(1) of the Pharmacy and Poisons Act 1979, makes the following Order: Citation 1 This Order may be cited as the Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017. Repeals and replaces the Third and Fourth Schedule of the Pharmacy and Poisons Act 1979 2 The Third and Fourth Schedules to the Pharmacy and Poisons Act 1979 are repealed and replaced with— “THIRD SCHEDULE (Sections 25(6); 27(1))) DRUGS OBTAINABLE ONLY ON PRESCRIPTION EXCEPT WHERE SPECIFIED IN THE FOURTH SCHEDULE (PART I AND PART II) Note: The following annotations used in this Schedule have the following meanings: md (maximum dose) i.e. the maximum quantity of the substance contained in the amount of a medicinal product which is recommended to be taken or administered at any one time. 1 PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 mdd (maximum daily dose) i.e. the maximum quantity of the substance that is contained in the amount of a medicinal product which is recommended to be taken or administered in any period of 24 hours. mg milligram ms (maximum strength) i.e. either or, if so specified, both of the following: (a) the maximum quantity of the substance by weight or volume that is contained in the dosage unit of a medicinal product; or (b) the maximum percentage of the substance contained in a medicinal product calculated in terms of w/w, w/v, v/w, or v/v, as appropriate.
    [Show full text]
  • Western Judicial Circuit Felony Drug Court
    Western Judicial Circuit Felony Drug Court (Athens-Clarke and Oconee Counties) PARTICIPANT HANDBOOK This handbook belongs to: 325 E. Washington Street, Suite 210 Athens, Georgia 30601 (706) 208-7078 (706) 613-3179 (fax) Table of Contents Welcome 3 Overview 4-5 Confidentiality 5 Treatment 5 Program Phases 6-10 Commencement 11 Program Rules 12-14 Program Fees 15 The Drug Court Team 15 Staffings 15 Court Appearances 16 Incentives 17 Sanctions and Treatment Responses 17 Termination 18 Drug/Chemical Testing 19 Prohibited Drugs/Permitted Medications 20-27 Travel/Leave Requests 27 Compliance & Home Visits/Job Checks, Searches 28 Search Requirements 28 Commencement Ceremony 29 Conclusion 29 Important Phone Numbers 30 Community Resources 31 Attachment I: Random Drug Screen Policy Attachment II: Urine Abstinence Testing/Incidental Alcohol Exposure Contract (original signed copy on file with Felony Drug Court) Attachment III: Emergency On-call Telephone Policy Attachment IV: Felony Drug Court Contract 2 Welcome to the Western Judicial Circuit Felony Drug Court! This Handbook was designed to answer your questions and provide specific information about what you must do in order to successfully complete the requirements of the Western Judicial Circuit Felony Drug Court Program. As a participant, you are expected to follow the instructions found in this Handbook, as well as the instructions of the Felony Drug Court Judge, Staff, and Treatment Provider. You will also be expected to comply with the treatment plan developed for you by your Treatment Provider. This handbook is not exhaustive and there is no possible way to make it complete and detailed to answer every question or situation that arises.
    [Show full text]
  • A 0.70% E 0.80% Is 0.90%
    US 20080317666A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2008/0317666 A1 Fattal et al. (43) Pub. Date: Dec. 25, 2008 (54) COLONIC DELIVERY OF ACTIVE AGENTS Publication Classification (51) Int. Cl. (76) Inventors: Elias Fattal, Paris (FR); Antoine A6IR 9/00 (2006.01) Andremont, Malakoff (FR); A61R 49/00 (2006.01) Patrick Couvreur, A6II 5L/12 (2006.01) Villebon-sur-Yvette (FR); Sandrine A6IPI/00 (2006.01) Bourgeois, Lyon (FR) (52) U.S. Cl. .......................... 424/1.11; 424/423; 424/9.1 (57) ABSTRACT Correspondence Address: Drug delivery devices that are orally administered, and that David S. Bradlin release active ingredients in the colon, are disclosed. In one Womble Carlyle Sandridge & Rice embodiment, the active ingredients are those that inactivate P.O.BOX 7037 antibiotics, such as macrollides, quinolones and beta-lactam Atlanta, GA 30359-0037 (US) containing antibiotics. One example of a Suitable active agent is an enzyme Such as beta-lactamases. In another embodi ment, the active agents are those that specifically treat colonic (21) Appl. No.: 11/628,832 disorders, such as Chrohn's Disease, irritable bowel syn drome, ulcerative colitis, colorectal cancer or constipation. (22) PCT Filed: Feb. 9, 2006 The drug delivery devices are in the form of beads of pectin, crosslinked with calcium and reticulated with polyethylene imine. The high crosslink density of the polyethyleneimine is (86). PCT No.: PCT/GBO6/OO448 believed to stabilize the pectin beads for a sufficient amount of time such that a Substantial amount of the active ingredi S371 (c)(1), ents can be administered directly to the colon.
    [Show full text]
  • 1This Action Arises Under the Patent Laws of the United States. See 35 U.S.C
    IN THE UNITED STATES DISTRICT COURT FOR THE EASTERN DISTRICT OF PENNSYLVANIA MCNEIL-PPC, INC., : Plaintiff, : CIVIL ACTION : v. : : L. PERRIGO COMPANY, : and PERRIGO COMPANY, : No. 01-1100 Defendants. : OPINION AND ORDER SCHILLER, J. June , 2002 This is a patent infringement action. Plaintiff McNeil-PPC, Inc. (“McNeil”) alleges Defendants L. Perrigo Company and Perrigo Company (collectively “Perrigo”) infringe four McNeil patents covering a popular version of the Imodium® Advanced antidiarrheal. In a Memorandum and Order issued April 3, 2002, I construed certain disputed claim terms pursuant to Markman v. Westview Instruments, Inc. , 517 U.S. 370 (1996). Beginning April 22, 2002, this matter was tried without a jury, and I enter the following Findings of Fact and Conclusions of Law as required by Rule 52(a) of the Federal Rules of Civil Procedure. 1 FINDINGS OF FACT I. BACKGROUND This action pits a manufacturer of national brand pharmaceuticals against its competitor, a generic drug manufacturer. Four patents owned by Plaintiff McNeil are at issue in this case: United States Patents 5,248,505 (“the ’505 patent”)(PTX1) and 5,612,054 (“the ’054 patent”)(PTX2) are 1This action arises under the patent laws of the United States. See 35 U.S.C. § 271(e)(2) and 21 U.S.C. § 355(j). Jurisdiction is based on 28 U.S.C. §§ 1331 and 1338(a). Venue is proper in this Court pursuant to 28 U.S.C. §§ 1391(c) and 1400(b). referred to as “the Garwin patents”; 2 United States Patents 5,679,376 (“the ’376 patent”)(PTX3) and 5,716,641 (“the ’641 patent”)(PTX4) are referred to as “the Stevens patents.” A.
    [Show full text]
  • World Journal of Pharmaceutical Research Yashasvi Et Al
    World Journal of Pharmaceutical Research Yashasvi et al . World Journal of Pharmaceutical SJIF Research Impact Factor 6.805 Volume 6, Issue 1, 998-1004. Research Article ISSN 2277– 7105 EFFICACY OF RACECADOTRIL COMPARED TO DIPHENOXYLATE IN ACUTE RADIATION ENTERITIS Dr. Yashasvi Suvarna*, Dr. Janaki M. G. and Dr. M. C. Shivamurthy Departments of Pharmacology and Radiation Oncology, M S Ramaiah Medical College and Hospitals, Bangalore. ABSTRACT Article Received on 08 Nov. 2016, Introduction: Radiation enteritis is one of the most common and Revised on 28 Nov. 2016, distressing complications of pelvic radiation. There are limited studies Accepted on 18 Dec. 2016 DOI: 10.20959/wjpr20171-7629 that have assessed the efficacy of antidiarrhoeals in radiation enteritis. This study was done to assess the efficacy of racecadotril versus diphenoxylate in acute radiation enteritis. Methods: This was a *Corresponding Author Dr. Yashasvi Suvarna prospective open label randomized study.50 patients were recruited Departments of into the study with 25 patients in each group. They received either Tab. Pharmacology and Racecadotril 100mg tid for 3 days or Tab. Diphenoxylate Radiation Oncology, M S Hydrochloride 2.5 mg(+ atropine 0.025 mg) tid for 3 days as an add on Ramaiah Medical College and Hospitals, Bangalore. to fluid supplementation. Results: The grade of radiation enteritis in both the groups were similar after 3 days of treatment with the drug (p=0.210).Only one patient in the racecadotril group required cessation of pelvic radiation due to hypokalemia. Conclusion: Racecadotril and diphenoxylate are both effective in treating radiation enteritis and are well tolerated. Further studies with racecadotril are warranted.
    [Show full text]
  • Narcotic Analgesics I Blanton SLIDE 1: We Will Be Spending the Next 90 Minutes Discussing Narcotic Analgesics- That Is Morphine, Oxycodone, Heroin, Etc
    Narcotic Analgesics I Blanton SLIDE 1: We will be spending the next 90 minutes discussing narcotic analgesics- that is morphine, oxycodone, heroin, etc. These drugs act primarily thru the opiate receptor system. I always like to begin by presenting two factoids that I believe illustrate the power of this system: (1) Ok imagine you are in pain! Now I tell you that I am going to give you an injection of morphine or heroin. Even if I instead give you an injection of just saline- 50% of you will report that your pain is significantly reduced- that is quite a placebo effect. However, if instead of saline I give you an injection of Naloxone, an opiate receptor antagonist- the placebo effect is eliminated. In other words you are activating your opiate receptor system to induce analgesia. (2) acupuncture can be used to reduce pain. However, Naloxone will block this effect- in otherwords the acupuncture is activating your opiate receptor system. SLIDE 1A: The use of narcotic analgesics for effective pain management has certainly had its flip side……. With prescription narcotic analgesics helping to fuel the current heroin epidemic…. Back to SLIDE 1: So narcotic analgesics. The name narcotic is somewhat misleading, because it implies narcosis or somnolence. The name opiate or opioid is more precise because it connotes analgesia, without causing sleep or loss of consciousness. SLIDE 2: The terms opiate or opioid, as you are probably aware, refers to opium, the crude extract of the Poppy plant, Papaver somniferum. Opium comes from the seed pod of the plant after the petals have dropped.
    [Show full text]
  • The Prevention and Treatment of Drug Misuse in Britain
    If you have issues viewing or accessing this file contact us at NCJRS.gov. .. " FW The prevention and treatment of drug misuse in Britain "I Issued by Rererence Division BRITISH INFORMATION SERVICES All Agency of the British Government 845 THIRD AVENUE, NEW YORK, N.Y. ]0022 This material is prepared, edited, issued or circulated by British Information Servic(!s, 845 Third Avenue, New York, N. Y.l0022, which is registered under the Foreign Agents Registration Act as an agent of the Brilish Government. This material is filed with the Department of Justice where the required registration statement is available for public inspection. Registration does not indicate approval 0/ the contents of this material by the United States Government. PRINTED IN ENGLAND BY TRADE UNION LABOR BY COLUNS AND WILSON LTD., ANDOVER The prevention and treatment of drug misuse in Britain Prepared by REFERENCE DIVISION CENTRhL OFFICE OF INFORMATION, LONDON Oclo~'er 1978 Quote No RS94S/78 CLASSIFICATION 4(c) N.B.-This pamphlet is i//tellded to be used for referellce purposes alld may be freely used ill preparing articles, speeches, broadcasts, elc. No acknowledgment is necessary. Please Ilote the date ofpreparation. Tire text gives general gUidance only, and should 1I0t be treated as an authoritative statement of the law. Pamphlets ill this series may be obtained from the Tllformation Office at tlte British Embassy, Consulate or High Commission in tile inquirer's Co/lIltl'Y of residellce. CONTENTS Page INTRODUCTION 1 BACKGROUND .. 3 PREVENTING DRUG MISUSE 8 The Law 8 Health Education 17 TREATMENT AND REHABILITATION .. 20 Narcotic Drug Misuse and the Role of the Clinics 20 Treating Other Forms of Drug Misuse 26 Rehabilitation 26 INFORMATION AND RESEARCH ., 29 APPENDICES 1.
    [Show full text]
  • Section B Changed Classes/Guidelines Final
    EPHMRA ANATOMICAL CLASSIFICATION GUIDELINES 2019 Section B Changed Classes/Guidelines Final Version Date of issue: 24th December 2018 1 A3 FUNCTIONAL GASTRO-INTESTINAL DISORDER DRUGS R2003 A3A PLAIN ANTISPASMODICS AND ANTICHOLINERGICS R1993 Includes all plain synthetic and natural antispasmodics and anticholinergics. A3B Out of use; can be reused. A3C ANTISPASMODIC/ATARACTIC COMBINATIONS This group includes combinations with tranquillisers, meprobamate and/or barbiturates except when they are indicated for disorders of the autonomic nervous system and neurasthenia, in which case they are classified in N5B4. A3D ANTISPASMODIC/ANALGESIC COMBINATIONS R1997 This group includes combinations with analgesics. Products also containing either tranquillisers or barbiturates and analgesics to be also classified in this group. Antispasmodics indicated exclusively for dysmenorrhoea are classified in G2X1. A3E ANTISPASMODICS COMBINED WITH OTHER PRODUCTS r2011 Includes all other combinations not specified in A3C, A3D and A3F. Combinations of antispasmodics and antacids are classified in A2A3; antispasmodics with antiulcerants are classified in A2B9. Combinations of antispasmodics with antiflatulents are classified here. A3F GASTROPROKINETICS r2013 This group includes products used for dyspepsia and gastro-oesophageal reflux. Compounds included are: alizapride, bromopride, cisapride, clebopride, cinitapride, domperidone, levosulpiride, metoclopramide, trimebutine. Prucalopride is classified in A6A9. Combinations of gastroprokinetics with other substances
    [Show full text]
  • MSIR (Morphine) Medical Facts from Drugs.Com 04/07/2015
    MSIR (morphine) medical facts from Drugs.com 04/07/2015 Browse all medications A B C D E F G H I J K L M N O P Q R S T U V W X Y Z Advanced Search Phonetic Search Drugs A-Z Pill Identifier Interactions Checker News Health Professionals Q & A Mednotes Apps Home → Conditions → Pain → MSIR Print Share Sign In or Register MSIR Related Information Availability Pregnancy Category Generic Name: morphine (MOR feen) Prescription only Risk cannot be ruled out Brand Name: AVINza, Kadian, MS Contin CSA Schedule WADA Class High potential for abuse Anti-Doping Classification Overview Side Effects Dosage Interactions More Reviews Average User Rating Reduce Nerve Pain Now Don't Let Neuropathy Symptoms Slow You Down. Get A Free Trial 1 User Review 9.0 Rate it! Now! Manufacturer What is MSIR (morphine)? Purdue Pharma LP Morphine is an opioid pain medication. An opioid is sometimes called a narcotic. Drug Class Morphine is used to treat moderate to severe Narcotic analgesics pain. Short-acting morphine is taken as needed for pain. Related Drugs The extended-release form of this medicine is Chronic Pain for around-the-clock treatment of pain. This tramadol form of morphine is not for use on an as- oxycodone needed basis for pain. Cymbalta Percocet Morphine is not for treating short-term pain just fentanyl after surgery unless you were already taking morphine morphine before the surgery. duloxetine methadone Morphine may also be used for purposes not Dilaudid listed in this medication guide. OxyContin Ultram More... Pain What is the most important information I should know about tramadol MSIR (morphine)? oxycodone naproxen You should not take this medicine if you have severe asthma or breathing problems, a blockage in acetaminophen your stomach or intestines, or a bowel obstruction called paralytic ileus.
    [Show full text]